Pramipexole

Pramipexole, sold under the brand Mirapex among others, is a medication used to treat Parkinson's disease and restless legs syndrome. In Parkinson's disease it may be used alone or together with levodopa. It is taken by mouth. Pramipexole is a dopamine agonist of the non-ergoline class.

Pramipexole was approved for medical use in the United States in 1997 and was first manufactured by Pharmacia and Upjohn. It is available as a generic medication. In 2022, it was the 193rd most commonly prescribed medication in the United States, with more than 2Template:Nbspmillion prescriptions.

Pramipexole bound to the Dopamine D3 receptor PDB - 7CMU

Medical uses

Pramipexole is used in the treatment of Parkinson's disease and restless legs syndrome. Safety in pregnancy and breastfeeding is unknown.

A 2008 meta-analysis found that pramipexole was more effective than ropinirole in the treatment of restless legs syndrome.

It is occasionally prescribed off-label for depression. Its effectiveness as an antidepressant may be a product of its strong partial agonistic activity on and preferential occupation of dopamine D₃ receptors at low doses (see table below); as well, the drug has been shown to desensitize the inhibitory D₂ autoreceptors but not the postsynaptic D₂ receptors, leading to an increase in dopamine and serotonin levels in the prefrontal cortex. Chronic administration of pramipexole may also result in desensitization of D₃ autoreceptors, leading to reduced dopamine transporter function. Trials have shown mixed results for depression.

Pramipexole has also been used as a treatment for REM sleep behaviour disorder, but it is not licensed for use in this disorder. Observational studies suggest it may reduce the frequency and intensity of REM sleep behavior disorder symptoms, but randomized controlled trials have not been performed, so the evidence for its role in this disorder is weak.

Side effects

Common side effects of pramipexole include:

• Headache
• Peripheral edema
• Hyperalgesia (body aches and pains)
• Nausea and vomiting
• Sedation and somnolence
• Decreased appetite and subsequent weight loss
• Orthostatic hypotension (resulting in dizziness, lightheadedness, and possibly fainting, especially when standing up)
• Insomnia
• Hallucinations (seeing, hearing, smelling, tasting or feeling things that are not there), amnesia and confusion
• Twitching, twisting, or other unusual body movements
• Unusual tiredness or weakness
• Pramipexole (and related D₃-preferring dopamine agonist medications such as ropinirole) can induce "impulsive-compulsive spectrum disorders" such as compulsive gambling, punding, hypersexuality, and overeating, even in people without any prior history of these behaviors. There have also been reported detrimental side effects related to impulse-control disorders resulting from off-label use of Pramipexole or other dopamine agonists in treating clinical depression. The incidence and severity of impulse-control disorders for those taking the drug for depression are not fully understood because the drug has not been approved for the treatment of depression and the first major studies of its efficacy in treating anhedonic depression were conducted in 2022. There have been anecdotal reports of abrupt and severe personality changes related to impulsivity and loss of self-control in a minority of patients regardless of the condition being treated, although the incidence of these side effects is not yet fully known.
• Augmentation:Template:Efn Especially when used to treat restless legs syndrome, long-term pramipexole treatment may exhibit drug augmentation, which is "an iatrogenic worsening of [restless legs syndrome] symptoms following treatment with dopaminergic agents" and may include an earlier onset of symptoms during the day or a generalized increase in symptoms.

Pharmacology

The activity profile of Pramipexole at various sites has been characterized as follows:

Activities of Pramipexole at various sites

Site	Affinity (Ki, nM)	Efficacy (Emax, %)	Action
D2S	3.3	130	Superagonist
D2L	3.9	99	Full agonist
D3	0.5	98	Full agonist
D4	3.9	91	Full agonist
Notes: Pramipexole also possesses lower affinity (500–10,000 nM) for the 5-HT1A, 5-HT1B, 5-HT1D, and α2-adrenergic receptors. It has negligible affinity (>10,000 nM) for the D1, D5, 5-HT2, α1-adrenergic, β-adrenergic, H1, and mACh receptors. All sites were assayed using human materials. Pramipexole is a superagonist at the presynaptic D2S receptor, S referring to a shorter amino acid sequence which desensitize overtime unlike postsynaptic D2L receptors.

Pramipexole Extended-Release 4.5mg Bottle 30 Count

While Pramipexole is used clinically (see below), its D₃-preferring receptor binding profile has made it a popular tool compound for preclinical research. For example, pramipexole has been used (in combination with D₂- and or D₃-preferring antagonists) to discover the role of D₃ receptor function in rodent models and tasks for neuropsychiatric disorders. Of note, it appears that pramipexole, in addition to having effects on dopamine D₃ receptors, may also affect mitochondrial function via a mechanism that remains less understood. A pharmacological approach to separate dopaminergic from non-dopaminergic (e.g. mitochondrial) effects of pramipexole has been to study the effects of the R-stereoisomer of pramipexole (which has much lower affinity to the dopamine receptors when compared to the S-isomer) side by side with the effects of the S-isomer. This property can be characterised using dopaminergic activity equivalent (a relative measure comparing doses of different doses of stereoisomers in mg).

Differences in median inhibitory concentration [nM] between stereoisomers of pramipexole

Receptor	S-isomer	R-isomer	S:R ratio	Souce
D2	4700	43000	9
	402	8330	21
	6.2	1800	290
D3	4.2	211	50
	0.94	610	649

Plasma Concentration of 0.25mg PO after a single dose.

Parkinson's disease is a neurodegenerative disease affecting the substantia nigra, a component of the basal ganglia. The substantia nigra has a high quantity of dopaminergic neurons, which are nerve cells that release the neurotransmitter known as dopamine. When dopamine is released, it may activate dopamine receptors in the striatum, which is another component of the basal ganglia. When neurons of the substantia nigra deteriorate in Parkinson's disease, the striatum no longer properly receives dopamine signals. As a result, the basal ganglia can no longer regulate body movement effectively and motor function becomes impaired. By acting as an agonist for the D₂, D₃, and D₄ dopamine receptors, pramipexole may directly stimulate the underfunctioning dopamine receptors in the striatum, thereby restoring the dopamine signals needed for proper functioning of the basal ganglia.

Pramipexole can increase growth hormone indirectly through its inhibition of somatostatin. Pramipexole has also been shown to be protective against dopaminergic-related methamphetamine neurotoxicity.

Plasma concentration of Mirapex and Mirapex ER at steady-state

Immediate-release pramipexole displays a T_max of approximately 2 hours and 3 hours if taken with a high-fat meal. Extended-release pramipexole displays a T_max of ~6 hours and ~8 hours if taken with food. The AUC of Pramipexole remains unaltered regardless of food presence. Steady-state is achieved within 3 days and 5 days for the IR and ER formulation respectively. Pramipexole is eliminated via the renal organic cation transporter as an unchanged drug showing no signs of any metabolism. Pramipexole has been shown to inhibit CYP2D6 with a K_i of 30μM which is significantly higher than the maximum approved dosage of 4.5mg/day thus any enzyme-mediated drug interactions are not clinically relevant. It comes in strengths of 0.125mg, 0.25mg, 0.5mg, 1mg, and 1.5mg instant release; the extended-release comes in 0.375mg, 0.75mg, 1.5mg, 2.25mg, 3mg, 3.75mg, and 4.5mg. The instant release is meant to be dosed three times daily for Parkinson's and once two hours before bedtime for restless leg syndrome. The extended-release is not approved for restless leg syndrome. It is not metabolized, with >90% of the dose excreted unchanged via SCL22A2/OCT2. Therefore, inhibitors of the renal organic cation transporter system (e.g., cimetidine ) will increase the area under the curve$\mathrm{\infty }$ by 50% and increase the t_1/2 by 40%.

Synthesis

4-Acetamidocyclohexanone (1) is reacted with bromine, yielding 2-bromo-4-acetamidocyclohexanone (2). Then, 2 reacts with thiourea, giving compound 3. Through reaction with HBr, amide is converted into a primary amine (compound 4), which then reacts with diethyl mesoxalate and tetrahydroborane, yielding pramipexole (5).

Society and culture

Brand names

Brand names include Mirapex, Mirapex ER, Mirapexin, Sifrol, Pexola, Pipexus, Glepark, Oprymea, Astepen, Calmolan, Erimexol, Ezaprev, Frodix, Galipeks, Labrixile, Mariprax, Medopexol, Mepimer, Minergi, Miparkan, Miraper, Miviren, Nulipar, Pacto, Panarak, Parim, Parixol, Parkipex, Parkyn, Parmital, Parpex, Pexa XR, Peximyr, Pexopar, Pisa, Portiv, Pradose, Pramigen, Pramipexin, Pramirol, Pramithon, Pranow, Prapex, Quera LP, Rampiex, Ramixole, Rapexole, Ritmorest, Axalanz, Biopsol, Derinik, Elderpat, Intaxel, Mirapapkin, Mirapezol, Movial, Muvend, Nervius, Neurosomat, Newmirex, Noxopran, Nulipar, Oxpola, Parmital, Periamid, Pralexan, Pramexol, Pramifer, Pramiola, Pramip, Pramitrem, Primizol, Ramipex, Rapexole, Simipex, Simpral, Stabil, Treminel, Trimexol, X-Tremble.

Research

Further Parkinson's disease symptoms treatment

Parkinson's disease, apart from motor symptoms, is associated with chronic pain, which is mediated through three different mechanisms: nociception, neuropathy and nociplasty. In animal models, it was shown that pramipexole alleviates allodynia and hyperalgesia caused by excessive glial cell (astrocytes, microglia) activation in the spinal cord, which is the causative effect of Parkinson's disease-relatet nociceptive pain. Pramipexole appears to exert this effect through its anti-inflammatory effect by inhibiting the release of several pro-inflammatory cytokines (TNF-α, IL-1β, IL-6, IL-8, IL-12 and IL-18). and NF-κB.

Cerebral ischemia and reperfusion injury

Pramipexole in combination with levodopa was shown to alleviate neurological repercussions, improve neuron morphology and their survival after cerebral ischemia-related reperfusion injury through ferroptosis inhibition (via Nrf2/GPX4/SLC7A11 pathway) or by mitochondrial membrane potential stabilization.

Traumatic brain injury

After traumatic brain injury, neurons can undergo necroptosis via necrosome formation and RIPK1 pathway. Pramipexole was shown to act as a neuroprotective agent by inducing hypothermia.

Psychiatry

Pramipexole has been evaluated for the treatment of sexual dysfunction experienced by some users of selective serotonin reuptake inhibitor antidepressants. It has shown effects on pilot studies in a placebo-controlled proof of concept study in bipolar disorder. It is also being investigated for the treatment of clinical depression, including neuroinflammatory subtypes via NLRP3 inflammasome pathway.

Other indications

Pramipexole is under clinical trials for the treatment of fibromyalgia, essential tremor, primary orthostatic tremor ('shaky leg syndrome'), persistent genital arousal disorder.

Derivatives

Derivatives of Pramipexole include CJ-998, CJ-1037, CJ-1638, CJ-1639, D-264, D-440, and D-512.